Compare AbCellera Biologics Inc (ABCL) vs Aptiv PLC (APTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Aptiv PLC — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Aptiv PLC trades at $57.63 (market cap $12.45B). The key difference: Aptiv PLC is far larger — about 5.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| ABCL | APTV | |
|---|---|---|
Market Cap | $2.35B | $12.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $76.82 |
52-Week Low | $2.78 | $52.57 |
Enterprise Value | $1.99B | $19.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
APTV trades at $58.85, down 0.07% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.71, exceeding expectations of $1.62. Revenue for 2025 reached $20.40B with a net income margin of 1.77%. Analyst consensus is strongly bullish with a $80.67 price target, though technical indicators show selling pressure with support at $58.
The outlook remains mixed: strong analyst support and solid cash flow trends contrast with narrow profit margins and bearish technicals. Key risks include margin compression and high debt levels, but institutional sentiment suggests potential upside if earnings momentum continues through Q2 results on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
